11,876 results match your criteria Bone Marrow Transplant.[Journal]


Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation.

Bone Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

Prophylactic donor lymphocyte infusions (DLI) are used to augment post-transplant immune recovery to reduce both infectious complications and disease recurrence. Preclinical studies implicate the naive T-cell subset as the primary driver of graft-versus-host disease (GvHD). In this phase I dose escalation study, we assessed the safety of a DLI that was depleted of CD45RA+ naive T cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0991-5DOI Listing

Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation.

Bone Marrow Transplant 2020 Jul 5. Epub 2020 Jul 5.

Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.

Allogeneic peripheral blood stem cell transplantation (PBSCT) is associated with an increased risk of severe acute and chronic graft-versus-host disease (GVHD) compared to bone marrow transplantation. Anti-thymocyte globulin (ATG) can reduce severe acute and chronic GVHD in PBSCT; however, an optimal dose of ATG remains undefined. We conducted a multicenter phase II study to investigate safety and efficacy of low-dose ATG (a total of 2 mg/kg Thymoglobulin) in patients undergoing HLA-matched PBSCT after myeloablative conditioning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0985-3DOI Listing

Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome.

Bone Marrow Transplant 2020 Jul 4. Epub 2020 Jul 4.

Department of Medicine, Division of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, IN, USA.

Sinusoidal obstruction syndrome (SOS) is a serious complication of hematopoietic stem cell transplantation (HSCT). Sirolimus plus tacrolimus is an accepted regimen for graft-versus-host disease (GVHD) prophylaxis, with both agents implicated as risk factors for SOS. We analyzed 260 consecutive patients who underwent allogeneic HSCT following myeloablative conditioning using total body irradiation (TBI)-based (n = 151) or chemotherapy only (n = 109) regimens, with sirolimus plus tacrolimus for GVHD prophylaxis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0987-1DOI Listing

Cardiac safe hematopoietic stem cell transplantation for systemic sclerosis with poor cardiac function: a pilot safety study that decreases neutropenic interval to 5 days.

Bone Marrow Transplant 2020 Jul 1. Epub 2020 Jul 1.

Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

We compared three fludarabine-based regimens for systemic sclerosis patients with a high-risk cardiac phenotype that according to EBMT criteria would be a contraindication for a high-dose cyclophosphamide (200 mg/kg) transplant regimen. All three regimens included fludarabine, ATG, and cyclophosphamide (60 mg/kg), while two regimens also included rituximab with or without IVIG. Treatment related mortality (TRM) was 2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0978-2DOI Listing

Liaisons Dangereuses? new drugs, physicians and the drug industry.

Bone Marrow Transplant 2020 Jul 1. Epub 2020 Jul 1.

Department of Medicine, Division of Hematology and Oncology, Case Western Reserve University, Cleveland, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0988-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327102PMC

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.

Bone Marrow Transplant 2020 Jun 30. Epub 2020 Jun 30.

Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0984-4DOI Listing

Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant 2020 Jun 30. Epub 2020 Jun 30.

Department of Medicine, Section of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada.

A Frailty and Functionality evaluation for alloHCT was implemented using existing resources. We describe the implementation of this evaluation across all ages and at first consultation, and correlate results with posttransplant outcomes in 168 patients. The evaluation consists of: Clinical Frailty Scale (CFS), Instrumental Activities of Daily Living (IADL), grip strength (GS), timed up and go test (TUGT), self-rated health question (SRH), Single question of Falls, albumin and C-Reactive Protein (CRP) levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0979-1DOI Listing
June 2020
3.570 Impact Factor

ABO incompatibile graft management in pediatric transplantation.

Bone Marrow Transplant 2020 Jun 27. Epub 2020 Jun 27.

Hospital for Children and Adolescents, Stammzelltransplantation und Immunologie, Klinik für Kinder- und Jugendmedizin, Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany.

Up to 40% of donor-recipient pairs in SCT have some degree of ABO incompatibility, which may cause severe complications. The aim of this study was to describe available options and survey current practices by means of a questionnaire circulated within the EBMT Pediatric Diseases Working Party investigators. Major ABO incompatibility (donor's RBCs have antigens missing on the recipient's cell surface, towards which the recipient has circulating isohemagglutinins) requires most frequently an intervention in case of bone marrow grafts, as immediate or delayed hemolysis, delayed erythropoiesis and pure red cell aplasia may occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0981-7DOI Listing

Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.

Bone Marrow Transplant 2020 Jun 26. Epub 2020 Jun 26.

Department of Hematology/Oncology/Stem Cell Transplantation, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.

The age of patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) has increased during the last decades, mainly due to improved reduced-intensity/toxicity conditioning protocols. A reduced-intensity conditioning based on fludarabin, carmustin/BCNU and melphalan (FBM) has been previously developed at our institution. Since we observed detrimental effects in individual patients with compromised lung function, efforts have been made in order to replace BCNU by thiotepa (FTM) to reduce toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0986-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319212PMC

Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation.

Bone Marrow Transplant 2020 Jun 25. Epub 2020 Jun 25.

Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Hematology and Transplantation Unit, Paris, France.

Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a retrospective study on outcomes and risk factors associated with acute and chronic steroid-refractory GVHD in a large cohort of 1207 patients receiving HSCT in Saint Louis Hospital between 2007 and 2017. Among patients who developed an acute and/or a chronic GVHD, the cumulative incidences of acute and chronic steroid-refractory disease were 31% and 48%, respectively, at day +100 and 1-year post-HSCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0977-3DOI Listing

Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells.

Bone Marrow Transplant 2020 Jun 24. Epub 2020 Jun 24.

National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.

Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (r/r Ph+ ALL) has an extremely poor prognosis. Chimeric antigen receptor T-cell (CART) therapy has acquired unprecedented efficacy in B-cell malignancies, but its role in the long-term survival of r/r Ph+ ALL patients is unclear. We analyzed the effect of CART on 56 adults with r/r Ph+ ALL who accepted split doses of humanized CD19-targeted CART after lymphodepleting chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0982-6DOI Listing

Therapy of posttransplant poor graft function with eltrombopag.

Bone Marrow Transplant 2020 Jun 22. Epub 2020 Jun 22.

Department of Pediatrics, Pediatric Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0975-5DOI Listing

Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study.

Bone Marrow Transplant 2020 Jun 20. Epub 2020 Jun 20.

Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.

HLA haploidentical hematopoietic stem cell transplantation (HSCT), i.e., HSCT from a 1-HLA-haplotype-mismatched family donor, has been successfully performed even as a second transplantation for posttransplant relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0980-8DOI Listing

The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study.

Bone Marrow Transplant 2020 Jun 19. Epub 2020 Jun 19.

Sorbonne University, Paris, France.

A mismatched unrelated (MMUD) donor represents an alternative therapeutic option for patients who need allogeneic hematopoietic cell transplantation (allo-HCT) and do not have a human leukocyte antigen (HLA) matched donor. We studied outcomes of patients with acute leukemia transplanted from ≥2 HLA allele MMUD. The study population consisted of 465 patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0974-6DOI Listing

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Bone Marrow Transplant 2020 Jun 18. Epub 2020 Jun 18.

Department Medicine V, University of Heidelberg, Heidelberg, Germany.

Purpose of this single-centre retrospective study was to assess the outcome of allogeneic hematopoietic cell transplantation (alloHCT) for relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) by intent-to-transplant (ITT). Included were all consecutive patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and peripheral T-cell lymphoma (PTCL) for whom a donor search was performed between 2004 and 2018. Primary endpoint was overall survival (OS) measured from search initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0976-4DOI Listing
June 2020
3.570 Impact Factor

Establishing the hematopoietic stem cell transplant (HSCT) in a developing country; the journey of HSCT in Semarang, Indonesia.

Bone Marrow Transplant 2020 Jun 17. Epub 2020 Jun 17.

Division of Hematology/Medical Oncology, Department of Internal Medicine, Medical Faculty of Diponegoro University and Dr. Kariadi Hospital, Semarang, Indonesia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0973-7DOI Listing

Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.

Bone Marrow Transplant 2020 Jun 15. Epub 2020 Jun 15.

Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China.

An amendment to this paper has been published and can be accessed via a link at the top of the paper. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0962-xDOI Listing

Towards new long-term composite 'Quality of Survival' endpoints.

Authors:
Jaap Jan Boelens

Bone Marrow Transplant 2020 Jun 12. Epub 2020 Jun 12.

Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0883-8DOI Listing

Hematopoietic stem cell transplantation from an infected SARS-CoV2 donor sibling.

Bone Marrow Transplant 2020 Jun 11. Epub 2020 Jun 11.

Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0969-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289075PMC
June 2020
3.570 Impact Factor

PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.

Bone Marrow Transplant 2020 Jun 11. Epub 2020 Jun 11.

Department of Laboratory Medicine - Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.

Acute myeloid leukemia (AML) is an immune-susceptible malignancy, as demonstrated by its responsiveness to allogeneic stem cell transplantation (alloSCT). However, by employing inhibitory signaling pathways, including PD-1/PD-L1, leukemia cells suppress T cell-mediated immune attack. Notably, impressive clinical efficacy has been obtained with PD-1/PD-L1 blocking antibodies in cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0966-6DOI Listing

Still learning the right way to administer melphalan in autologous transplantation.

Bone Marrow Transplant 2020 Jun 10. Epub 2020 Jun 10.

Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0971-9DOI Listing

Cord blood transplants supported by unrelated donor CD34 progenitor cells.

Bone Marrow Transplant 2020 Jun 9. Epub 2020 Jun 9.

Department of Medicine, Division of Hematology/Oncology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.

Alternative donor transplantation with the haplo-cord platform allows the use of a lower-dose single umbilical cord blood unit (CBU) by co-infusion of third-party CD34-selected cells from a haploidentical relative, which provides early transient engraftment while awaiting durable CBU engraftment. In our experience, ~15% of patients lack a suitable haploidentical donor. Here we report 26 patients who underwent haplo-cord transplant using CD34-selected partially matched unrelated donor grafts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0959-5DOI Listing

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis.

Bone Marrow Transplant 2020 Jul 9;55(7):1297-1304. Epub 2020 Jun 9.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

In the presence of effective treatment options for systemic light chain (AL) amyloidosis, autologous stem cell transplantation (ASCT) is sometimes deferred after stem cell collection. We designed this retrospective study to compare overall survival (OS) between patients who proceed directly to ASCT after stem cell collection and those who defer ASCT. We included patients with AL amyloidosis who had stem cell collection at Mayo Clinic, Minnesota, from 2004 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0964-8DOI Listing

Taxonomy.

Authors:
Shaun R McCann

Bone Marrow Transplant 2020 Jun 8. Epub 2020 Jun 8.

Haematology, Emeritus, Trinity College, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0968-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276959PMC

Decisions in HCT and wine-making.

Authors:
Shaun McCann

Bone Marrow Transplant 2020 Jun 7. Epub 2020 Jun 7.

Haematology Emeritus, Trinity College, Dunlin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0960-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276097PMC

Containment of a traceable COVID-19 outbreak among healthcare workers at a hematopoietic stem cell transplantation unit.

Bone Marrow Transplant 2020 07 1;55(7):1491-1492. Epub 2020 Jun 1.

Hematopoietic Stem Cell Transplantation Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0958-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262489PMC

Value and affordability of CAR T-cell therapy in the United States.

Bone Marrow Transplant 2020 May 30. Epub 2020 May 30.

Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite) were approved by the FDA for use after showing groundbreaking results in relapsed/refractory B-cell malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0956-8DOI Listing

A pilot feasibility study of non-myeloablative allogeneic hematopoietic stem cell transplantation for refractory Crohn Disease.

Bone Marrow Transplant 2020 May 28. Epub 2020 May 28.

Division of Immunotherapy, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0953-yDOI Listing

Interrogating the impact of KIR ligand mismatch in engraftment following HLA-disparate stem cell transplantation.

Bone Marrow Transplant 2020 May 27. Epub 2020 May 27.

Stem Cell Transplant Program, University Hospitals Seidman Cancer Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.

The effects of donor-derived natural killer (NK) cell alloreactivity on disease relapse and transplant-related mortality following allogeneic stem cell transplantation have been described while the impact of recipient-derived NK cell alloreactivity on donor engraftment is not well known. Epitopes of HLA Class I molecules act as ligands for NK cell killer immunoglobulin-like receptors (KIR) regulating their cytotoxicity. As such, NK cell alloreactivity is predictable from KIR ligand mismatches between donors and recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0957-7DOI Listing

Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.

Bone Marrow Transplant 2020 Jul 23;55(7):1317-1325. Epub 2020 May 23.

Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.

Reduced-intensity conditioning (RIC) regimens have been widely used for allogeneic hematopoietic cell transplantation (HCT) in elderly patients. After the emergence of tyrosine kinase inhibitor (TKI), most patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) now achieve negative results for minimal residual disease (MRD) at HCT. In this study, we evaluated patients aged 50 years or more with Ph-positive ALL who received TKI before HCT, achieved negative-MRD at HCT, and underwent their first allogeneic HCT between 2008 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0951-0DOI Listing

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level.

Bone Marrow Transplant 2020 May 23. Epub 2020 May 23.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Acute graft-versus-host disease (aGVHD) is a serious complication after stem cell transplantation and is associated with high non-relapse mortality. If steroid treatment as first-line therapeutic approach fails, treatment options are limited. In retrospective studies, ruxolitinib, a selective Janus kinase 1/2 inhibitor as well as extracorporeal photopheresis (ECP) could show high efficacy in treatment of steroid refractory acute and chronic GVHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0952-zDOI Listing

Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma.

Bone Marrow Transplant 2020 May 23. Epub 2020 May 23.

Hematology and Inserm CIC 1402, CHU, Poitiers, France.

Mobilization of peripheral blood stem cells (PBSC) can be performed using plerixafor, which is expensive, or high-dose cyclophosphamide (HDCy). We hypothesized that the overall cost of mobilization with plerixafor might not be greater if the cost of complication management was considered. We performed a cost analysis of these two strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0940-3DOI Listing

Conditioning regimen for allogeneic bone marrow transplantation in children with acquired bone marrow failure: fludarabine/melphalan vs. fludarabine/cyclophosphamide.

Bone Marrow Transplant 2020 Jul 23;55(7):1272-1281. Epub 2020 May 23.

Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Fludarabine/cyclophosphamide-based conditioning regimens are standard in bone marrow transplantation (BMT) for acquired bone marrow failure in children, however, graft failure may occur. Using the data from a nationwide transplantation registry, we compared the outcomes of children aged <16 years with acquired aplastic anemia and refractory cytopenia of childhood who underwent allogeneic BMT with either fludarabine/melphalan (n = 71) or fludarabine/cyclophosphamide (n = 296) between 2000 and 2016. The fludarabine/melphalan regimen provided excellent outcomes, with 3-year overall survival and failure-free survival rates of 98% and 97%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0948-8DOI Listing

Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies.

Bone Marrow Transplant 2020 May 21. Epub 2020 May 21.

Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

To investigate which reduced-intensity conditioning (RIC)/reduced-toxicity conditioning (RTC) is superior for umbilical cord blood transplantation (UCBT) for lymphoid malignancies, we retrospectively compared three widely used RIC/RTC regimens: fludarabine/melphalan/total body irradiation (FM-TBI, n = 524), fludarabine/cyclophosphamide/total body irradiation (FC-TBI, n = 96), and fludarabine/busulfan/total body irradiation or melphalan (FB-based, n = 159). Among patients with acute lymphoblastic leukemia (ALL) (n = 314), there were no differences in overall survival (OS) by conditioning regimen. Among patients with malignant lymphoma (ML) (n = 465), FM-TBI and FC-TBI regimens had similar OS, whereas FB-based regimen had lower OS (hazard ratio [HR], 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0905-6DOI Listing

Absence of damaging effects of stem cell donation in unrelated donors assessed by FISH and gene variance screening.

Bone Marrow Transplant 2020 Jul 21;55(7):1290-1296. Epub 2020 May 21.

Anthony Nolan Research Institute, The Royal Free Hospital, Pond Street, London, NW3 2QG, UK.

Astract: Granulocyte-Colony-Stimulating factor (G-CSF) is currently the standard mobilising agent for peripheral blood stem cell (PBSC) donation. Concerns that it may trigger chromosome aberrations similar to those observed in leukaemia patients were refuted but long-term effects of G-CSF mobilisation on genome integrity remains unclear. In the setting of a multi-centre clinical trial we screened blood samples from 50 PBSC donors at cellular and gene level for aberrations common in haematological malignancies using fluorescence in situ hybridisation (FISH) and next generation sequencing (NGS) assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0945-yDOI Listing

Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance.

Bone Marrow Transplant 2020 Jul 20;55(7):1305-1316. Epub 2020 May 20.

BMT Unit, Department of Pediatric Hematology Oncology, Schneider Children's Medical Center, Petach Tikva, Israel.

Graft versus host disease (GvHD) remains a limiting factor for successful hematopoietic stem cell transplantation (HSCT). T cells and antigen-presenting cells (APCs) are major components of the hematopoietic G-CSF mobilized peripheral blood cell (MPBC) graft. Here we show that a short incubation (2 h) of MPBCs with hexameric Fas ligand (FasL) selectively induces apoptosis of specific donor T cell subsets and APCs but not of CD34 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0941-2DOI Listing

Building a hematopoietic cell transplantation outcomes registry in Mexico.

Bone Marrow Transplant 2020 May 16. Epub 2020 May 16.

Hematology Service, Unidad Médica de Alta Especialidad "Manuel Avila Camacho", Instituto Mexicano del Seguro Social, Puebla, PL, Mexico.

The aim of this study was to assess the feasibility of hematopoietic cell transplantation (HCT) data collection using an electronic platform at Mexican centers. Four public centers performing HCT in adults were included. A cloud-based electronic platform in Spanish was developed to allow real-time registration of demographic, clinical, and outcomes variables. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0944-zDOI Listing

Community acquired respiratory virus infections in adult patients undergoing umbilical cord blood transplantation.

Bone Marrow Transplant 2020 May 15. Epub 2020 May 15.

Department of Hematology, University Hospital La Fe, Valencia, Spain.

Characteristics and risk factors (RFs) of community-acquired respiratory virus (CARV) infections after umbilical cord blood transplantation (UCBT) are lacking. We retrospectively analyzed CARV infections in 216 single-unit myeloablative UCBT recipients. One-hundred and fourteen episodes of CARV infections were diagnosed in 62 (29%) patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-020-0943-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227453PMC